Long non-coding RNA MYOSLID functions as a competing endogenous RNA to regulate MCL-1 expression by sponging...

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Long non-coding RNAs (lncRNAs) are increasingly recognized as crucial regulators in human cancers.
• The specific roles and clinical implications of most lncRNAs in gastric cancer (GC) are not yet fully understood.

Purpose of the Study:

• To investigate the biological function, mechanism, and clinical significance of lncRNA MYOSLID in gastric cancer.
• To elucidate the regulatory pathway involving lncRNA MYOSLID, miR-29c-3p, and MCL-1 in GC development.

Main Methods:

• Differential expression analysis of lncRNA MYOSLID in GC tissues versus non-cancerous tissues using The Cancer Genome Atlas (TCGA) data.
• In vitro experiments to assess the impact of lncRNA MYOSLID knockdown on GC cell proliferation and apoptosis.
• In vivo studies using a nude mouse xenograft model to confirm the role of lncRNA MYOSLID in tumorigenesis.
• Mechanism investigation revealing lncRNA MYOSLID acts as a competing endogenous RNA (ceRNA) for miR-29c-3p.

Main Results:

• lncRNA MYOSLID expression is significantly upregulated in GC tissues and correlates with tumor size, AJCC stage, invasion depth, and patient survival.
• Knockdown of lncRNA MYOSLID inhibits GC cell proliferation and induces apoptosis in vitro, and suppresses tumor growth in vivo.
• lncRNA MYOSLID functions as a ceRNA for miR-29c-3p, leading to the de-repression of its target gene, MCL-1.

Conclusions:

• The lncRNA MYOSLID-miR-29c-3p-MCL-1 regulatory axis is pivotal in the pathogenesis of gastric cancer.
• These findings highlight lncRNA MYOSLID as a potential biomarker and therapeutic target for human GC.